Savara
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Savara and other ETFs, options, and stocks.About SVRA
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis.
SVRA Key Statistics
Stock Snapshot
As of today, Savara(SVRA) shares are valued at $4.86. The company's market cap stands at 998.78M, with a P/E ratio of -8.53.
As of 2026-10-12, Savara(SVRA) stock has fluctuated between $4.81 and $5.05. The current price stands at $4.86, placing the stock +1.1% above today's low and -3.7% off the high.
The Savara(SVRA)'s current trading volume is 787.08K, compared to an average daily volume of 2.93M.
In the last year, Savara(SVRA) shares hit a 52-week high of $7.01 and a 52-week low of $3.35.
In the last year, Savara(SVRA) shares hit a 52-week high of $7.01 and a 52-week low of $3.35.
SVRA News
Savara (SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, has drawn attention after recent price pressure, with the stock...
JPMorgan initiated coverage of Savara (SVRA) with an Overweight rating and $12 price target The firm sees “plenty of catalysts” for Savara in the near-term, inc...
Analyst ratings
100%
of 9 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.